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Abstract 
 
As a result of neuro-vascular coupling, the functional effects of antipsychotics in human 
brain have been investigated in both healthy and clinical populations using haemodynamic 
markers such as regional Cerebral Blood Flow (rCBF). However, the relationship between 
observed haemodynamic effects and the pharmacological action of these drugs has not been 
fully established. Here, we analysed Arterial Spin Labelling (ASL) rCBF data from a 
placebo-controlled study in healthy volunteers, who received a single dose of three different 
D2 receptor (D2R) antagonists and tested the association of the main effects of the drugs on 
rCBF against normative population maps of D2R protein density and gene-expression data. In 
particular, we correlated CBF changes after antipsychotic administration with non-
displaceable binding potential (BPND) template maps of the high affinity D2-antagonist 
Positron Emission Tomography (PET) ligand [18F]Fallypride and with brain post-mortem 
microarray mRNA expression data for the DRD2 gene from the Allen Human Brain Atlas 
(ABA). For all antipsychotics, rCBF changes were directly proportional to brain D2R 
densities and DRD2 mRNA expression measures, although PET BPND spatial profiles 
explained more variance as compared with mRNA profiles (PET R2 range= 0.20-0.60, 
mRNA PET R2 range 0.04-0.20, pairwise-comparisons all pcorrected<0.05). In addition, the 
spatial coupling between ∆CBF and D2R profiles varied between the different antipsychotics 
tested, possibly reflecting differential affinities. Overall, these results indicate that the 
functional effects of antipsychotics as measured with rCBF are tightly correlated with the 
distribution of their target receptors in striatal and extra-striatal regions. Our results further 
demonstrate the link between neurotransmitter targets and haemodynamic changes 
reinforcing rCBF as a robust in-vivo marker of drug effects. This work is important in 
bridging the gap between pharmacokinetic and pharmacodynamics of novel and existing 
compounds. 
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Introduction 
 
Antipsychotics are still the preferred choice for the treatment of conditions such as 
schizophrenia and other mental health disorders with psychotic features (Stroup et al., 2009). 
The main target of most of these compounds is the dopamine D2 receptor (D2R) (Burt et al., 
1977; Farde et al., 1986) where they act as antagonists or partial agonists. D2R occupancy of 
antipsychotics has been assessed in vivo with emission tomography in healthy controls and 
clinical populations (Agid et al., 2007; Kapur et al., 1995; Nyberg et al., 1995) and it has also 
been linked with treatment response (Kapur et al., 2000). While antipsychotics have been 
well characterized in terms of their pharmacokinetics (PK) and clinical response, their impact 
on brain physiology and function is still not well understood. A deeper understanding of these 
effects is crucial to uncover biological mechanisms driving their clinical efficacy as well as 
their side effects.  
Functional effects of antipsychotics in the brain have been investigated using different 
neuroimaging tools. Seminal work using Positron Emission Tomography (PET) 
[18F]fluorodeoxyglucose and [15O]H2O showed that drug naïve first episode psychosis 
patients, had increased glucose utilization after treatment with antipsychotics (DeLisi et al., 
1985; Holcomb et al., 1996) and greater perfusion (Goozee et al., 2014; Miller et al., 2001; 
1997) in the basal ganglia. Similar results were also obtained in healthy volunteers using a 
single dose of antipsychotics (Kim et al., 2013; Mehta, 2003). Studies using Arterial Spin 
Labelling (ASL), a Magnetic Resonance Imaging (MRI) sequence designed to quantitatively 
measure regional cerebral blood flow (rCBF), found results in line with the earlier PET 
studies. In particular,  (Fernández-Seara et al., 2011) reported increased rCBF in the striatum 
and thalamus in healthy volunteers after a single oral dose of 10 mg of metoclopramide (a 
D2R antagonist) and (Handley et al., 2013) showed that both haloperidol 3 mg (a D2R 
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antagonist) and aripiprazole 10 mg (a D2R partial agonist with 5-HT2a antagonism 
properties) increased rCBF in the striatum in healthy volunteers with a larger effect size for 
haloperidol. Recently, we tested the effects of a single clinical effective dose of different 
antipsychotics (Hawkins et al., 2018). Consistent with the existing literature, 3 mg 
haloperidol, 2 mg risperidone and 0.5 mg risperidone increased striatal rCBF as compared 
with placebo.  
One of the major limitations of pharmacological MRI studies stands on the 
haemodynamic nature of the main functional measures (e.g. BOLD and rCBF). According to 
the neurovascular coupling model (Attwell and Iadecola, 2002; Logothetis et al., 2001) 
changes in haemodynamic MRI measures reflect a complex cascade of cellular, metabolic 
and vascular events associated with changes in neuronal activity (Heeger and Ress, 2002; 
Hoge et al., 1999; Singh, 2012). In line with this model, the main effects of drug may be 
interpreted as the result of dose-dependent enhanced or reduced pre- or post-synaptic activity 
due to the action of the drug on its targets (Khalili-Mahani et al., 2017). Although many 
antipsychotics bind to numerous receptors, the effects on rCBF have been tacitly attributed to 
D2R blockade. In particular, D2R antagonism would lead to enhanced neurotransmitter 
turnover in the dopaminergic synapses inducing metabolic activity and therefore perfusion 
demands (Goozee et al., 2014; Handley et al., 2013). The findings of altered dopamine 
synthesis capacity after acute antipsychotics administration in human volunteers and rats 
support this hypothesis (Hertel et al., 1996; Ito et al., 2009; Vernaleken et al., 2008). 
However, since MRI does not measure neuronal activity directly, making a link between 
neuro-receptor binding and haemodynamic effects of these compounds requires a degree of 
conjecture. In addition, in the case of dopaminergic drugs, MRI hemodynamic changes have 
also been related to non-neuronal mechanisms including the action of D1-like receptors on 
vessels and D2-like receptors (mainly D3R) on perivascular astrocytes and endothelial cells 
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(Choi et al., 2006; Krimer et al., 1998). For these reasons, despite the body of evidence, the 
neurochemical mechanisms underlying CBF changes after antipsychotics administration 
remain unclear. The use of multimodal approaches, e.g. combining MR measures with ex-
vivo autoradiography (Dukart et al., 2018), have started to fill this gap of knowledge.     
Receptor occupancy theory posits that the magnitude of the drug response is a function of 
receptor availability (Clark, 1970; Ploeger et al., 2009). In other words, incremental changes 
in functional response correspond to increments of the fraction of receptors bound. This 
relationship also depends on specific characteristics of each compound, such as receptor 
affinity (i.e. Ki). This basic pharmacology principle has been used to characterize the spatial 
profile of drug effects in the brain (also called “drug fingerprinting”) assuming that brain 
regions with high density of the target receptor will show higher magnitude of drug effects 
(Khalili-Mahani et al., 2017). This approach has been proposed to describe MRI changes to 
dopaminergic drugs in preclinical data (Mandeville et al., 2013). Indeed, a monotonic 
increase in regional Cerebral Blood Volume (rCBV) has been observed following injection of 
an increasing dose of the D2/D3 antagonist radiotracer [11C]raclopride in the striatum of two 
male rhesus macaques (Sander et al., 2013). Interestingly, [11C]raclopride non-displaceable 
binding potential changes (BPND) reflecting changes in D2/D3 receptor occupancy, correlated 
with the amplitude of hemodynamic changes (i.e. rCBV): the higher the dose the larger rCBV 
increase; and in time: BPND variation and changes in rCBV showed similar temporal profiles. 
The same group also found an inverse relationship between receptor occupancy and rCBV 
with the selective D2/D3 agonist quinpirole in male rhesus macaques (i.e. rCBV decrease in 
face of dose-dependent increase of receptor occupancy) (Sander et al., 2016). Both studies 
provide evidence for a neurovascular coupling mechanism linking MR haemodynamic 
changes and D2/D3 receptors pharmacological modulation in non-human primates although 
they are limited to the striatal region.  
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The aim of the present work is to test in humans whether rCBF changes induced by a 
single dose of different antipsychotics co-varies with in vivo measures of D2R distribution. In 
particular, we employed two datasets from healthy volunteers (Hawkins et al., 2018) to 
evaluate the spatial correlation between rCBF variation in the placebo vs antipsychotic 
comparison against the population-based receptor density profiles derived from human PET 
scans using the high affinity D2/D3 antagonist [18F]Fallypride (Mukherjee et al., 1995). We 
also investigated the same relationship at the gene expression level using post-mortem 
mRNA expression measures of the DRD2 gene (the gene coding for D2R) extracted from the 
Human Allen Brain Atlas (ABA) (Hawrylycz et al., 2012). Brain mRNA expression variation 
across brain regions has been shown to be associated with resting state fMRI networks 
suggesting that brain hemodynamic response may be linked to the architecture of the human 
brain transcriptome (Hawrylycz et al., 2015; Richiardi et al., 2015). Here, brain microarray 
mRNA expression data was chosen as a proxy to protein-level receptor density in the human 
brain. In fact, while post-transcriptional events may alter the relationship between gene 
expression and protein synthesis (Liu et al., 2016), brain mRNA expression maps have been 
shown to predict in vivo proteins level as measured with PET (Beliveau et al., 2017; Rizzo et 
al., 2014).  
Following the receptor occupancy theory and the neurovascular coupling model 
proposed by (Sander et al., 2013) we hypothesized that there will be a detectable linear 
relationship between main effects of antipsychotics on CBF measures and D2R receptor 
density profiles evaluated at the protein and gene expression level. Even though brain 
microarray mRNA expression data from the ABA is noisier and more discrete (i.e. limited 
number of samples) than the PET BPND maps, we expect CBF increases after antipsychotics 
to be linearly associated also with DRD2 mRNA expression spatial profiles.  However, given 
the fact that mRNA expression only approximates cellular protein levels due to post-
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transcriptional regulatory mechanisms we predict microarray data to explain less variance in 
CBF changes than PET derived maps. 
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Materials and Methods 
 
 
Participants and study design  
Data were collected as part of a project approved by the National Research Ethics Service 
Committee London – Brent (REC reference: 13/LO/1183). Details about participants, 
protocol and study design have been described in detail in (Hawkins et al., 2018). Briefly, 
forty-two healthy male subjects were enrolled in a double-blind, placebo-controlled, 
randomised, fully counterbalanced, three-session crossover design. Participants were 
randomised into two equal parallel study groups (Group 1 age mean/SD 27.6/6.9; Group 2 
age mean/SD 28.3/6.3). In the first group participants received placebo, 7.5 mg of olanzapine 
(OLA), or 3 mg of haloperidol (HAL) on each study day. In the second group, participants 
received placebo, 0.5 or 2 mg risperidone (lowRIS and highRIS respectively). All but lowRIS 
dosage were chosen in order to achieve on average at least 60% of D2 receptor occupancy 
(Kapur et al., 2000; Tauscher et al., 2004). On dosing day, participants followed a 
standardised regime. The MRI scan was performed at the time of predicted peak level of 
plasma concentration of the drug after oral administration (Tmax): approximately 5 hours after 
drug administration for Group 1 and 2 hours for Group 2 (de Greef et al., 2011; Midha et al., 
1989; Nyberg et al., 1997; Tauscher et al., 2002). Study days were seven days apart to allow 
washout between sessions. After the final visit, a follow-up phone call was made to monitor 
potential adverse events related to the study drugs. 
 
MRI acquisition and pre-processing  
All scans were conducted on a GE MR750 3 Tesla scanner using a 12-channel head coil. 
ASL image data were acquired using a 3D pseudo-continuous ASL sequence (3DpCASL) 
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with a multi-shot, segmented 3D stack of axial spirals (8-arms) readout with a resultant 
spatial resolution (after re-gridding and Fourier Transformation) of 2x2x3mm. Four control-
label pairs were used to derive a perfusion weighted difference image. The labelling RF pulse 
had a duration of 1.5s and a post-labelling delay of 1.5s. The sequence included background 
suppression for optimum reduction of the static tissue signal. A proton density image was 
acquired in 48s using the same acquisition parameters in order to compute the CBF map in 
standard physiological units (ml blood/100g tissue/min). Pre-processing of all CBF data was 
performed exactly as described in (Hawkins et al., 2018) (for further details please see 
Supplementary Materials).  
 
Receptor density profiles 
Figure 1 shows the general framework of the analysis. D2R profiles where extracted from an 
independent [18F]Fallypride PET template obtained by averaging six binding potential  
(BPND) whole brain maps acquired in healthy young volunteers (age range: 18-30 years) who 
did not participate in the drug study (Dunn et al., 2009). [18F]Fallypride is a D2/D3 receptor 
antagonist and it is a well-established PET radiotracer in the study of D2-like receptor 
distribution in the brain (Mukherjee et al., 1995). Compared with other D2-like antagonist 
radiotracers (e.g. [11C]raclopride), [18F]Fallypride has higher affinity and higher signal-to-
noise ratios in vivo and therefore provides reliable quantitative measures of D2R 
concentration including extra-striatal brain regions (Mukherjee et al., 2002; Stark et al., 
2018). The [18F]Fallypride template was segmented with the Desikan-Killiany Atlas (Desikan 
et al., 2006) and for each of the 85 Regions of Interest (ROIs) of the template, the voxel-wise 
mean BPND value was extracted with the flslmeants function implemented in the Functional 
Software Library suite (FSL, FMRIB, Oxford, UK). Conventional parametric modelling of 
regional BPND was performed by using the cerebellum as reference region (Ichise et al., 
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2003). Therefore, both left and right cerebellar ROIs (namely “rh_cerebellum_cortex” and 
“lh_cerebellum_cortex”) were excluded from correlation analyses with CBF profiles. To 
compare the contribution of striatal vs extra-striatal regions to this association, we also 
extracted BPND profiles from a [11C]raclopride template obtained from a matchted group of 
healthy controls (Grecchi et al., 2014) (see Supplementary Material).  
 
CBF profiles 
CBF profiles were obtained from maps of CBF changes at the group level. In particular, for 
each antipsychotic, a group-wide paired T-test was performed in SPM12 for each drug vs 
placebo. Whole brain total blood flow was added as a covariate of no interest in the model to 
account for peripheral (global) drug effects and between-subjects variability in global brain 
perfusion (Handley et al., 2013; Viviani et al., 2013; 2009). For each antipsychotic the main 
effect of the drug was tested using group voxel-wise paired t-tests with cluster-level FWE 
correction (alpha = 0.05, cluster defining threshold = 0.001) as implemented in SPM12. In 
agreement with previous studies (Handley et al., 2013; Hawkins et al., 2018), we identified  
statistically significant increases in CBF after drug administration (against placebo) and have 
thus focussed on this contrast in the remainder of this work.  Therefore, DRUG>PLACEBO 
contrast maps for each antipsychotic where segmented by using the Desikan-Killiany Atlas 
(Desikan et al., 2006) using the same approach used for the extraction of receptor profiles. 
This resulted in 85 ∆CBF profiles measuring the antipsychotic induced increase of CBF in 
each ROI. For consistency with the receptor profile data, we carried out correlation analyses 
excluding the two cerebellum ROIs.  
 
Statistical analysis for the ∆CBF/receptor density profiles correlations 
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To test the associations between ∆CBF profiles (derived for each antipsychotic) and D2/D3 
receptor density profiles, linear regression models as implemented in SPSS were used (IBM, 
SPSS Statistics, Version 23). Normal distribution of the residuals of the regression models 
were tested by Shapiro-Wilk test. BPND data were transformed using a natural logarithmic 
function (ln) so that the residuals conformed to a normal distribution. For all linear regression 
models Mahalanobis distance and Cook’s distance were computed in order to explore the 
presence of multivariate outliers and estimate the presence of highly influential data points. 
To identify multivariate outliers,  Mahalanobis distance values were compared to a chi-square 
distribution with degrees of freedom equal to the number of variables (two in this case) with 
p= 0.001 (Finch, 2012; Tabachnick and Fidell, 2013). Any data point with Cook’s distance 
higher than 1 was considered as highly influential outlier and excluded from the analysis 
(Cook and Weisberg, 1982). To further control for the effect of extreme observation we also 
used the bias-corrected accelerated bootstrap technique as implemented in SPSS (Efron and 
Tibshirani, 1986) with 10,000 resamples. Non-parametric Spearman’s correlations between 
∆CBF profiles and receptor BPND profiles were also performed as a countercheck. In 
addition, Fisher’s r-to-z transformation was performed to test pairwise significance of the 
difference between correlation coefficients of ∆CBF profiles between different 
antipsychotics. Asymptotic covariance method was adopted to account for the fact that 
correlations had one variable in common (Lee and Preacher, 2013) 
 
mRNA profiles and genetic correlations  
DRD2 gene brain microarray mRNA expression values were extracted from ABA data 
(http://human.brain-map.org) by using the Multimodal Environment for Neuroimaging and 
Genomic Analysis (MENGA) toolbox (http://www.nitrc.org/projects/menga/) (Rizzo et al., 
2016). The same toolbox was used to carry out correlations with ∆CBF profiles of each 
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antipsychotic. First, antipsychotics’ contrast images (DRUG>PLACEBO) were resampled in 
the ABA space. Then, each CBF image sample was spatially matched with the corresponding 
genomic ABA sample within a search window of a sphere of 5mm radius centred on the MNI 
coordinates of the ABA sample. Both CBF contrast image and ABA data were then 
segmented using the list of structures (N= 169) provided by the ABA (Hawrylycz et al., 
2012). A subset of 89 structures (ROIs), each containing at least one genomic sample for all 
the six ABA brains (donors), was selected to perform correlations between ∆CBF profiles 
and gene expression. For each donor, samples data were converted from their original log2 
intensity in z-scores using mean and standard deviation as normalization factor for a given 
subject. This was done to minimize bias related to inter-donor variability in the ABA dataset. 
For the DRD2 gene a unique profile was obtained by selecting the probe which expression 
values were highly consistent across donors. In particular, distributions of expression values 
for all the probes were evaluated across donors, retaining the probe with the most symmetric 
and least skewed distribution. In the case of multiple samples within the same ROI, the 
average between samples within the ROI was calculated (Rizzo et al., 2016).  
After completing the matching and the extraction of ∆CBF and gene expression profiles, two 
different correlations were performed: 1) between-donors correlation or gene auto-correlation 
returning the biological variability of the spatial profile of mRNA expression between donors 
(the higher the gene autocorrelation the lower the heterogeneity in mRNA expression spatial 
profile between donors); 2) correlation between each gene expression and the ∆CBF by ROIs 
also called cross-correlation. A Principal Component Analysis (PCA) on mRNA expression 
measures of the 6 ABA donors was performed beforehand in order to extract the component 
that accounted at least for the 95% of the total variance in the mRNA expression data. In 
particular, the PCA was performed on an 89x6 matrix (89 ROIs by 6 donors) and represented 
a consistent spatial mRNA expression profile across all donors. This component was then 
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used in the regression model against CBF profiles. Significance was assessed with a 
bootstrapping approach resulting in a chance likelihood of the correlation coefficient 
expressed as a %. More specifically, ROIs were permuted within donors repeating the 
correlation between PCA component and CBF profiles 1,000 times, in order to obtain a 
measure of the likelihood that the correlation found was different from chance level. For 
further details on ABA mRNA processing and analysis see Supplementary Material and 
(Rizzo et al., 2016). A multivariate spatial correlation using MENGA was also performed 
between DRD2 gene expression profiles and [18F]Fallypride BPND maps (see Supplementary 
Material). As for protein density profile analysis, Fisher’s r-to-z transformation was 
performed to test pairwise significance of the difference between correlation coefficients of 
∆CBF profiles between different antipsychotics and also between PET and mRNA profiles.  
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Figure 1. General framework of the analysis. Group-level map showing main effect of drug was computed 
for each antipsychotic. The resulting maps and the [18F]Fallypride PET template were segmented into 83 
ROIs by using the Desikan-Killiany Atlas (Desikan et al., 2006). For each ROI ∆CBF profiles and 
[18F]Fallypride BPND template values were extracted and then correlated. DRD2 gene brain microarray 
mRNA expression values were extracted from ABA data (http://human.brain-map.org) (Hawrylycz et al., 
2012). MENGA software (http://www.nitrc.org/projects/menga/)  (Rizzo et al., 2016) was used to extract 
DRD2 mRNA expression profiles which then entered multivariate correlation analysis against ∆CBF 
profiles (please refer to Material and methods and Supplementary Material for a more detailed 
description). 
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Results 
 
Main effect of antipsychotic on CBF 
Group paired T-tests revealed that all antipsychotics but olanzapine, produced a statistically 
significant increase of CBF in basal ganglia, in particular in the striatum with haloperidol 
causing the largest increase as compared with lowRIS and highRIS. In particular HAL>PLA 
t-contrast revealed a significant cluster in the left Putamen; OLA>PLA t-contrast revealed a 
significant cluster in the righ parietal cortex and in the right parahippocampus; lowRIS>PLA 
t-contrast revealed a significant cluster in the left caudate; highRIS>PLA t-contrast revealed a 
significant cluster in the left caudate. None of the DRUG<PLA t-contrast revealed 
statistically significant clusters. Full statistics and voxel-wise t-maps are in Supplementary 
Material.  
 
CBF changes with D2 receptor profiles correlations 
All antipsychotic ∆CBF profiles significantly correlated with [18F]Fallypride BPND template 
values (Table 1 and Figure 2). HAL ∆CBF had the strongest correlation with [18F]Fallypride 
BPND template (Rlinear= 0.78) followed by RIS (Rlinear= 0.73 and Rlinear= 0.72 for lowRIS and 
highRIS respectively) and OLA (Rlinear= 0.48). Results from linear models and non-
parametric Spearman correlations were consistent. In all linear regressions, none of the data 
points were identified as a highly influential outlier (all Cook’s distances> 1) or multivariate 
outliers (all Mahalanobis distances p>0.01). Results were retained after 10,000 resamples (all 
bootstrapped p<0.01). The rank of order and Rlinear values matched the variation in affinity 
with D2 receptor (McCormick et al., 2010), with the stronger the association between ∆CBF 
profiles and D2 receptor densities the lower the Ki (Table 1 and Figure  4). In the pairwise 
correlation comparisons we found significant difference for HAL vs OLA (z= 5.46), lowRIS 
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vs OLA (z= 4.19) and vs highRIS vs OLA (z= 3.90) (all ptwo-tailed < 0.01, Bonferroni 
corrected, Figure 4). All the other comparisons were not significant. To compare striatal vs 
extra-striatal contributions to this association we also performed correlations between ∆CBF 
and receptor density profiles by extracting BPND values from a [11C]raclopride PET template. 
We found weaker correlation with [11C]raclopride BPND template as compared with 
[18F]Fallypride BPND template (see Supplementary material).  
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Figure 2. Scatterplots of ∆CBF/receptor density profiles correlations. Top row: scatterplot of the correlation 
between HAL ∆CBF profiles and [18F]Fallypride BPND template (left) and of the correlation between OLA 
∆CBF profiles and [18F]Fallypride BPND template (right). Bottom row: scatterplot of the correlation between 
lowRIS ∆CBF profiles and [18F]Fallypride BPND template (left) and of the correlation between highRIS ∆CBF 
profiles and [18F]Fallypride BPND template (right). Dashed lines indicate 95% confidence bands. 
 
 
mRNA expression correlations 
The average correlation coefficient (R2) of the genomic autocorrelation analysis for the 
DRD2 gene was 0.575 (standard deviation= 0.058) for the six donors. This result indicated 
good stability between donors of DRD2 mRNA expression spatial profile (Rizzo et al., 2016).  
For the different antipsychotic drugs, the correlation coefficients were all positive and 
statistically significant (Figure 3 and Table 1) and also significantly lower than those 
obtained for the PET template (PET R2 range= 0.20-0.60; mRNA PET R2 range 0.04-0.20; 
pairwise-comparisons all p<0.05). As for the correlation with [18F]Fallypride values, genomic 
mRNA expression correlations qualitatively mirrored Ki differences (McCormick et al., 
2010) between antipsychotics at D2R (Figure  4). However, none of the pairwise comparisons 
between correlation coefficients between antipsychotics were statistically significant after 
correction for multiple comparisons. 
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Figure 3. Scatterplots of the genomic correlation. For all scatterplots on the y axis normalized 
DRUG>PLACEBO CBF changes and on the x axis DRUG>PLACEBO CBF changes predicted by the first 
Principal Component of the mRNA expression measures of the 6 ABA donors. Top right: HAL; Top left: OLA; 
Bottom right: lowRIS; Bottom left: highRIS. Dashed lines indicate 95% confidence bands. 
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Table 1. Summary of the correlations of ∆CBF profiles D2 receptor profiles ([18F]Fallypride BPND 
template) and of genomic multivariate cross-correlations of antipsychotics’ ∆CBF profiles with DRD2 
mRNA expression profiles. 
 
 
 
Figure 4. Differential strength of association between ∆CBF and D2R profiles. Heat maps showing z-values for 
the pairwise comparison of correlations. Colour bar indicates z-scores. On the left correlations with 
[18F]Fallypride BPND template values, on the right correlations with mRNA microarray data from the ABA. 
HAL= haloperidol, OLA= olanzapine, lowRIS = low dose of risperidone, highRIS = high dose of risperidone. 
The following tests were performed HAL vs OLA, HAL vs lowRIS, HAL vs highRIS, lowRIS vs OLA, 
highRIS vs OLA, highRIS vs lowRIS.  
 
DRUG>PLA 
contrast 
[18F]Fallypride BPND template 
DRD2 mRNA 
expression 
 Rlinear plinear Spearman rho pSpearman R 
Chance 
likelihood 
HAL + 0.78 p<0.001 0.61 p<0.001 + 0.34 0 % 
OLA + 0.48 p<0.001 0.51 p<0.001 + 0.21 0 % 
lowRIS + 0.73 p<0.001 0.76 p<0.001 + 0.43 0 % 
highRIS + 0.72 p<0.001 0.61 p<0.001 + 0.45 2 % 
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Discussion 
 
The aim of the present study was to investigate the relationship between the effects of single 
clinical effective doses of antipsychotics on rCBF and receptor distribution profiles in the 
brain as indexed by [18F]Fallypride BPND values extracted from a template map and brain 
DRD2 mRNA expression profiles. Consistently with our hypothesis, we found that for all 
compounds there was a spatial coupling between drug-induced CBF changes and D2 receptor 
density profiles (at both protein and gene expression level). In addition, we found that mRNA 
data explained less variance in CBF changes than PET derived map.  
 
 
Receptor density profiles 
The association between CBF changes induced by all antipsychotics and receptor brain 
spatial distribution of D2R matches earlier evidence in non-human primates showing large 
CBF increases after injection of the D2 antagonist PET tracer [11C]raclopride in brain regions 
with high D2R density (Sander et al., 2013). This suggests that the relationship between the 
physiological response to D2R antagonist and D2R availability described  by (Sander et al., 
2013) in preclinical models also exists in vivo in humans. Furthermore, we have shown that 
the relationship between ASL-CBF increases after antipsychotic administration also matched 
[18F]Fallypride BPND template values in extra-striatal ROIs significantly populated by D2R 
such as the thalamus and the amygdala, even though they show lower BPND template values 
as compared with striatal ROIs. These results extend earlier evidence (Sander et al., 2016) 
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and suggest that the linear coupling between CBF response to dopaminergic drugs and D2R 
concentration might also be a valid model outside the striatum. This interpretation is also 
supported by the weaker correlation of ∆CBF with [11C]raclopride BPND template as 
compared with [18F]Fallypride BPND template (Supplementary Material). Of note, in  Sander 
et al., (2016; 2013) the functional measure was rCBV instead of rCBF. However, given the 
tight association between rCBV changes and rCBF changes (Ito et al., 2005), we believe this 
difference will not affect the interpretation of our findings.  
 
Microarray mRNA expression data 
We found that for all antipsychotics, the ∆CBF profiles also correlated with microarray 
mRNA expression data extracted from the ABA. All genomic correlations were positive and 
therefore in the same direction of [18F]Fallypride BPND template linear models. Notably, 
microarray mRNA expression measures explained less variance in ∆CBF than [18F]Fallypride 
BPND template values. This is consistent with our hypothesis motivated by the existence of a 
large variability between mRNA expression and protein synthesis due to post-transcriptional 
regulation mechanisms (Liu et al., 2016). Our findings are consistent with previous works 
that have linked the spatial architecture of the brain transcriptome to brain structure (Grecchi 
et al., 2017; Veronese et al., 2015), function (Hawrylycz et al., 2015; Richiardi et al., 2015) 
and in vivo measures of brain proteins (Gryglewski et al., 2018; Rizzo et al., 2016; 2014; 
Veronese et al., 2016). Here we could show that post mortem brain mRNA expression data 
may potentially be used to map also variations in MRI functional response to drug 
stimulation. However, such mapping has still many limitations to be addressed in order to 
adopt it extensively in the context of pharmacological-MRI studies. For instance, it might be 
difficult to use mRNA expression mapping in neurotransmitter systems where protein 
synthesis is highly dependent on post-transcriptional regulation mechanisms (e.g. serotonin 
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system) (Beliveau et al., 2017; Rizzo et al., 2014). While further studies are needed to fully 
validate this mRNA expression-MRI approach, it might be especially valuable for profiling 
the functional effects of drugs with poorly characterized or unknown targets. Interestingly, as 
for the correlation with receptor density profiles, the rank order of correlations between 
∆CBF and DRD2 mRNA expression measures mirrored affinity profiles of the compounds, 
although these differences were only numerical.  It is worth noting that the variance 
explained by genomic correlation was lower than the PET correlations (Table 1), which 
might have reduced the chance of detecting any significant difference on the pairwise 
comparison between the correlation coefficients.  
These findings represent a further evidence supporting the hypothesized PK/PD model of 
antipsychotic effect of CBF measures (Mandeville et al., 2013). Indeed, we were able to 
show that quantitative measures of brain functional effect of antipsychotics (i.e. CBF 
changes) are directly associated with receptor density measures. However, intrinsic 
limitations of the ABA dataset should be considered when evaluating mRNA/∆CBF 
relationships. First the number of available ABA donors is limited (N= 6) and therefore only 
approximates population-level brain mRNA expression templates. However, despite this 
limitation, ABA data has been showed to be able to predict brain protein densities (Beliveau 
et al., 2017; Gryglewski et al., 2018; Rizzo et al., 2016; 2014; Veronese et al., 2016) and 
other neuroimaging measures (Hawrylycz et al., 2015; Richiardi et al., 2015; Ritchie et al., 
2018). Another limitation is that different approaches have been proposed to analyse this 
dataset (French and Paus, 2015; Gryglewski et al., 2018). The fact that different strategies in 
ABA dataset processing could affect reproducibility of the findings is under debate 
(Arnatkeviciute et al., 2018). We have also analysed the mRNA/∆CBF correlations using a 
different methods that employs whole-brain voxel-wise mRNA expression maps obtained 
from variograms (Gryglewski et al., 2018). The results of this anaysis were comparable with 
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the analysis performed in MENGA (Supplementary Materials). Therefore we believe that it is 
unlikely that this methological issue could have biased our results.  
 
Differential strength of association between ∆CBF and receptor density profiles.  
The correlation strength between ∆CBF and receptor density measured with PET varied 
between the different antipsychotics tested (Figure 4). One possible interpretation of this 
difference might be related to the differential affinities for these compounds to D2R (Dukart 
et al., 2018). Our data seems to be in line with this hypothesis. In fact, the strengths of the 
association were higher for antipsychotics with higher affinity for D2R (Table 1 and Figure 
S1).  In particular, HAL was the drug with the highest correlation coefficient and the lowest 
Ki, whereas OLA showed the lowest correlation coefficient and the highest Ki. Both lowRIS 
and highRIS were in the middle between HAL and OLA. Another possible interpretation 
might be that related with the different secondary affinities between the drugs. For instance, 
for compounds with an high affinity with 5HT2a receptors like risperidone and olanzapine, 
part of the effect on CBF might also be linked with a mechanism different from D2R 
blockade (Goozee et al., 2014). In fact, both OLA and RIS as well as other second-generation 
antipsychotics (e.g. aripiprazole) showed decreases in CBF especially in cortical areas with a 
mechanism that is possibly mediated by 5HT2a receptors (Handley et al., 2013; Lahti et al., 
2005). We did not find differences in correlations between the two different doses of 
risperidone, despite the fact that they do show different effect size in CBF increase (as shown 
in Figure 2 bottom row). This might indicate that the coupling between the measurable 
physiological effects and target receptor distribution can be detected regardless the dose of 
the compound if that dose is able to produce detectable functional effects. Nonetheless, 
differences in brain disposition of antipsychotics have been reported in previous studies 
(Kornhuber et al., 2006; Rodda et al., 2006). In particular, animal data suggested that 
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antipsychotics (including the ones considered in the present work) show different blood-brain 
barrier penetration and brain clearance leading to dissimilar spatial distribution in the brain 
(Loryan et al., 2016). Even though these dissimilarities have been reported to be only 
moderate (Loryan et al., 2016), brain disposition is a factor to be considered in addition to 
receptor affinity when linking the pharmacodynamics of each antipsychotic with receptor 
occupancy. Therefore, without maps of brain deposition variation, conclusions regarding the 
D2R affinities and strength of associations between receptors and CBF are necessarily 
incomplete. 
 
Limitations 
A number of limitations need to be considered for the present study. First, we used 
population-based profiles of D2R density as the spatial architecture of D2R is typically 
consistent across individuals (Rizzo et al., 2014; Veronese et al., 2016). For example, the 
striatum always has higher D2R density than the thalamus which in turn has higher D2R 
density than the cortex. However, variance in density between individuals within the same 
brain region (Farde et al., 1995) may drive inter-individual differences in the drug functional 
response. Individualized receptor profiles mapping is therefore necessary to bring more 
precision to the method and to further validate the present findings. Nevertheless, normative 
atlases for protein and mRNA expressions have proven useful in many different applications, 
suggesting that the core spatial architecture of the brain receptor systems is consistent across 
individuals (Beliveau et al., 2017; Rizzo et al., 2016; 2014; Veronese et al., 2016). 
In addition, we considered only local effects by matching CBF changes and D2R receptor 
density measures with the same ROIs. However, studies in patients and healthy volunteers 
showed that antipsychotics also produce changes in functional connectivity in rs-fMRI 
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suggesting the existence of downstream effects (Cole et al., 2013; Sarpal et al., 2015) that 
were not included in our analyses. 
As discussed above, increases in CBF after acute antipsychotic challenge have been usually 
interpreted as the result of a neuronal metabolic changes due to D2R blockade. D2-like 
receptors are also present in perivascular astrocytes and endothelial cells modulating brain 
hemodynamic changes. However these receptors are mainly D3R and not D2R (Choi et al., 
2006). Together with the knowledge that the affinity of these compounds for D2R is higher 
than for D3R we expect the change in CBF is mainly neuronal in origin. In addition, both 
risperidone and olanzapine, but not haloperidol, act as antagonists at the serotonin-2a 
receptors (5HT2a) (Meltzer, 1999). Blockade of 5HT2a receptors on smooth-muscle cells of 
brain arteries has been shown to induce relative vasodilation in animal models (i.e. blocking 
vasoconstriction caused by the endogenous ligand serotonin) (Kovács et al., 2012). 
Therefore, the degree to which these non-neuronal effects contribute to the associations 
described here is not known. Finally, we believe that the limited sample size offered by the 
ABA (N = 6) could have undermined power in detecting a linear relationship between mRNA 
data and rCBF changes. This factor could also be an alternative explanation of the difference 
we found between mRNA and PET correlations with rCBF.  
 
 
Conclusion 
 
Understanding the link between neurochemical changes and brain function is crucial to 
uncover mechanisms underlining the effects of psychopharmacological treatment and 
between-subjects variability in response. In this work we investigated the case of 
antipsychotics whose functional effect, evaluated as changes in CBF measures, mirror the 
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well-known spatial distributions of their main target (i.e. D2R). The characterisation of the 
haemodynamic response using this multimodal approach might be applicable also for other 
classes of drugs and it becomes particularly valuable for profiling compounds known to bind 
to multiple targets or with unknown or poorly characterised targets. Finally, our work 
demonstrates that the use of MRI 3D pCASL as a measure of regional CBF offers an 
efficient, non-invasive tool to investigate CNS penetration in the process of psychotropic 
drug development that is also linked with brain chemistry. 
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